You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 2.6% | 3.8% |
Div Cover | 3.7 | 2.6 |
Op Mrgn | 22.2% | 27.2% |
ROCE | 67.1% |
Latest | Forecast | |
---|---|---|
P/E | 10.6 | 0.0 |
PEG | 1.0 | 9.8 |
Price / Revenue | 2.2 | 2.1 |
Price / Book value | 5.3 |
Latest | Forecast | |
---|---|---|
Revenue | 3.4% | 2.2% |
PBT | 7.7% | n/a |
EPS | 11.0% | 0.4% |
DPS | -4.5% | 1.9% |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2019-12-31 | 33,754.00 | 6,221.00 | 123.90p | 17.9 | 4.8 | 4% | 80.00p | 3.6% |
2020-12-31 | 34,099.00 | 6,968.00 | 115.90p | 14.5 | -2.2 | -6% | 80.00p | 4.8% |
2021-12-31 | 24,696.00 | 3,599.00 | 90.56p | 22.2 | -1.0 | -22% | 80.00p | 4.0% |
2022-12-31 | 29,324.00 | 5,628.00 | 139.70p | 10.3 | 0.2 | 54% | 44.00p | 3.1% |
2023-12-31 | 30,328.00 | 6,064.00 | 155.10p | 9.4 | 0.8 | 11% | 42.00p | 2.9% |
GSK's endometrial cancer drug receives FDA approval Sharecast News | 24 Apr |
---|---|
GSK posts promising results from gonorrhoea treatment trial Sharecast News | 17 Apr |
GSK meningococcal vaccine accepted by US FDA for review Sharecast News | 16 Apr |
US FDA accepts new indication filing for Jemperli | 24-Apr-24 07:01 |
---|---|
Director/PDMR Shareholding | 19-Apr-24 15:30 |
Director/PDMR Shareholding | 17-Apr-24 15:30 |
GSK announces additional EAGLE-1 results | 17-Apr-24 07:05 |
Results from long-term data relating to Shingrix | 17-Apr-24 07:01 |